SHASQI, INC.
Click Activated Protodrugs (CAP) platform using bioorthogonal click chemistry to activate drugs at specific disease sites
- Sector
- Biotech
- Headquarters
- San Francisco, CA
- Total capital
- $9.1M
- Federal grants
- $9.1M
- 10 awards · 2021–2025
- Rank in peer group#48 of 514
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 18 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · CEACAM5-targeted activation of potent chemotherapeutics via bioorthogonal click chemistry$1.1M
- Federal grantHealth and Human S · Phase II · Antigen-targeted activation of Topo1 inhibitors via click chemistry$432K
- Federal grantHealth and Human S · Phase II · Antigen-targeted activation of Topo1 inhibitors via click chemistry$1.6M
- Federal grantHealth and Human S · Phase II · Antibody-guided localized activation of bioorthogonal protodrugs via click chemistry$1.2M
- Federal grantHealth and Human S · Phase II · Assessing the safety and efficacy of SQ3370 in a phase 1b dose-expansion cohort at the recommended Phase 2 dose in patients with advanced sarcoma$322K
- Federal grantHealth and Human S · Phase II · Antibody-guided localized activation of bioorthogonal protodrugs via click chemistry$782K
- Federal grantHealth and Human S · Phase II · Assessing the safety and efficacy of SQ3370 in a phase 1b dose-expansion cohort at the recommended Phase 2 dose in patients with advanced sarcoma$299K
Show 3 earlier federal awards
- Federal grantHealth and Human S · Phase II · Immune Biomarker Assessment and Manufacturing Development for SQ3370-001, a first-in-human phase I dose-escalation clinical trial to test a novel treatment against advanced solid tumors$801K
- Federal grantHealth and Human S · Phase II · Assessing the safety and efficacy of SQ3370 in a phase 1b dose-expansion cohort at the recommended Phase 2 dose in patients with advanced sarcoma$1.4M
- Federal grantHealth and Human S · Phase II · Immune Biomarker Assessment and Manufacturing Development for SQ3370-001, a first-in-human phase I dose-escalation clinical trial to test a novel treatment against advanced solid tumors$1.2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#48 · top 9%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 0 granted of 18- PendingDaptomycin-Trans-cyclooctene conjugateUSPTOApplication 62626978
- PendingSynthesis of Trans-cyclooctene-glycine-doxorubicinUSPTOApplication 62623329
- PendingSynthesis of Trans-cyclooctene Carboxylic Acid MMAEUSPTOApplication 62623245
Show all 18 patent records
- Daptomycin-Trans-cyclooctene conjugateApplication 62626978Pending
- Synthesis of Trans-cyclooctene-glycine-doxorubicinApplication 62623329Pending
- Synthesis of Trans-cyclooctene Carboxylic Acid MMAEApplication 62623245Pending
- Antibiotic Conjugates Of Trans-cyclooctenesApplication 62609943Pending
- Bioorthogonal Compositions for Treatment of Bacterial Infections and CancerApplication 62568586Pending
- Bio-orthogonal Strategy For In Vivo Activation Of Antibiotic ProdrugsApplication 62515948Pending
- Material-guided delivery of antibiotics against MRSAApplication 62507973Pending
- Use of Bioorthogonal Compositions with Implanted Medical DeviceApplication 62483121Pending
- Bioorthogonal Compositions for Localized TherapiesApplication 62483081Pending
- Bioorthogonal CompositionsApplication 62483163Pending
- Bioorthogonal CompositionsApplication PCTUS2016051394Pending
- Tco Activated Immolative Linkers For Targeted Drug DeliveryApplication 62381442Pending
- Tco Activated Immolative Linkers For Targeted Drug DeliveryApplication 62357647Pending
- Tco Activated Immolative Linkers For Targeted Drug DeliveryApplication 62344341Pending
- In-vivo Biorthogonal Chemistry Enables Local Hydrogel And Systemic Pro-drug To Treat Soft Tissue SarcomaApplication 62327924Pending
- Targeted TherapyApplication 62387480Pending
- Targeted TherapyApplication 62242896Pending
- Methods And Therapeutic Compositions For Delivery Of Agents In A SubjectApplication 62216858Pending
Related companies, and why
- TAMBO, INC.Shares a founder: JOSE MEJIAONETO
- BOSTON INTERACTOME LLCSimilar federal contract value in Biotech · null in contracts
- Resilience Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- ALEPH THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
- PRIMITY BIO, INC.Similar federal contract value in Biotech · null in contracts
- Mountain Valley MD Holdings Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .